前立腺癌患者血清中の前立腺特異抗原の検討

Abstract

1)未治療前立腺癌31例で前立腺特異抗原(PA)が異常値を示すものの割合は, stage A1 50%, C(pN0, NX) 50%, D1 80%, D2 100%であった.2)病理組織分化度とPA値との間に関係はなかった.3)組織学的に診断された前立腺肥大症, 前立腺炎, 尿路結石でそれぞれ52%, 18%, 0%に異常値をみた.4)Stage D2に対する内分泌療法後, 低分化型のものは, 正常化しにくい傾向にあった.5)再燃例は, 制癌例に比し, PA異常値を示すものの割合が高く, 再燃の診断の一助となると考えた.PA異常値で臨床的に制癌とした例に数ヵ月後, 再燃したものがあった

Prostatic specific antigen (PA) level was determined with a Wako test kit (Japan) for prostatic cancer and others. The incidence of abnormal values of PA in untreated prostatic cancer, was 50, 50, 80, and 100% for stage A1, C (pN0, NX), D1 and D2 cancers, respectively. Grade was not related to the level of PA. Prostatic hypertrophy, prostatitis and urinary stone showed a false positive rate of 52, 18 and 0%, respectively. The level of PA was not correlated to those of prostatic acid phosphatase (RIA). In 31% of the cases, the elevated PA decreased 4 weeks after start of endocrine treatment. Elevated PA in low grade cancer was not normalized as much as that in high and moderate grade cancers. The positive rate of PA in the serum of reactivated patients was significantly higher than that of the patients with cancer under good control by endocrine treatment.